Psychiatry and Clinical Neurosciences Reports最新文献_第5页

Suicide attempt during ramelteon addition to flunitrazepam: A case report 在氟硝西泮中添加雷美替胺期间企图自杀：病例报告

Psychiatry and Clinical Neurosciences Reports Pub Date : 2024-01-18 DOI: 10.1002/pcn5.168

Takeshi Terao

引用次数: 0

Alterations in the hub structure of whole‐brain functional networks in patients with drug‐naïve schizophrenia: Insights from electroencephalography‐based research 药物治疗无效精神分裂症患者全脑功能网络中枢结构的改变：基于脑电图研究的启示

Psychiatry and Clinical Neurosciences Reports Pub Date : 2024-01-10 DOI: 10.1002/pcn5.164

Tomoaki Ishibashi, S. Nobukawa, Mayuna Tobe, Mitsuru Kikuchi, Tetsuya Takahashi

{"title":"Alterations in the hub structure of whole‐brain functional networks in patients with drug‐naïve schizophrenia: Insights from electroencephalography‐based research","authors":"Tomoaki Ishibashi, S. Nobukawa, Mayuna Tobe, Mitsuru Kikuchi, Tetsuya Takahashi","doi":"10.1002/pcn5.164","DOIUrl":"https://doi.org/10.1002/pcn5.164","url":null,"abstract":"This study aimed to identify atypical hubs in the whole‐brain networks of patients with schizophrenia (SZ) and examine the effects of antipsychotic medications, using electroencephalography (EEG) data.We estimated the functional connectivity across all electrodes by applying the phase lag index to the EEG signals of 21 drug‐naïve patients with SZ and 31 age‐matched healthy controls. Betweenness centrality (BC), a measure of hub status, was calculated for each electrode and frequency band. Data from 14 patients were re‐evaluated after initiating treatment with antipsychotic medications.BC values decreased significantly at the Fz site in the beta band, decreased significantly at Pz in the gamma band, and increased significantly at O1 in the gamma band among patients with SZ. These changes persisted after antipsychotic treatment and were unrelated to clinical symptoms.The abnormal hub topology we observed, especially in the high‐frequency band, may reflect the pathophysiology of SZ, and this study highlights the utility of BC analysis of EEG data for detecting alterations in the whole‐brain networks of patients with SZ.","PeriodicalId":507124,"journal":{"name":"Psychiatry and Clinical Neurosciences Reports","volume":" 36","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139627160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of vortioxetine for winter depression in bipolar disorder: A case report 伏替西汀治疗双相情感障碍患者冬季抑郁的疗效：病例报告

Psychiatry and Clinical Neurosciences Reports Pub Date : 2024-01-10 DOI: 10.1002/pcn5.163

Yusei Yamaguchi, Shunsuke Takagi, H. Takahashi, G. Sugihara

{"title":"Effectiveness of vortioxetine for winter depression in bipolar disorder: A case report","authors":"Yusei Yamaguchi, Shunsuke Takagi, H. Takahashi, G. Sugihara","doi":"10.1002/pcn5.163","DOIUrl":"https://doi.org/10.1002/pcn5.163","url":null,"abstract":"We present a case report on the efficacy of the short‐term application of vortioxetine in managing winter depression in patients with seasonal bipolar disorder (BP). Standard treatment strategies for BP may not adequately address seasonal depressive symptoms during winter in patients with seasonal BP patterns. Depressive symptoms during winter may be linked to seasonal changes in serotonin transporter binding, such as a decrease in synaptic serotonin levels, necessitating alternative approaches. Although antidepressants, including vortioxetine, are effective in treating seasonal monopolar depression, their efficacy and safety in treating depression in patients with seasonal BP patterns remain unclear.This case report focuses on a 44‐year‐old male patient diagnosed with seasonal BP who had recurrent depressive episodes, specifically during winter. Notably, the patient had a significant decrease in recurrent episodes after short‐term seasonal vortioxetine use without inducing mania or rapid cycling.Our study highlights the potential effectiveness of a seasonal, short‐term treatment strategy with antidepressants, including vortioxetine, for winter depression in individuals with BP.","PeriodicalId":507124,"journal":{"name":"Psychiatry and Clinical Neurosciences Reports","volume":" 49","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139628020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interpersonal psychotherapy for comorbid prolonged grief disorder and persistent depressive disorder in a Japanese patient: A case report 人际心理疗法治疗一名日本患者的长期悲伤障碍和持续性抑郁障碍：病例报告

Psychiatry and Clinical Neurosciences Reports Pub Date : 2023-12-01 DOI: 10.1002/pcn5.161

Takuya Okami, Yuko Toshishige, M. Kondo, Junya Okazaki, Hiroko Mizushima, Tatsuo Akechi

{"title":"Interpersonal psychotherapy for comorbid prolonged grief disorder and persistent depressive disorder in a Japanese patient: A case report","authors":"Takuya Okami, Yuko Toshishige, M. Kondo, Junya Okazaki, Hiroko Mizushima, Tatsuo Akechi","doi":"10.1002/pcn5.161","DOIUrl":"https://doi.org/10.1002/pcn5.161","url":null,"abstract":"Prolonged grief disorder (PGD) is a new diagnostic entity. However, treatment for PGD is not yet available. Interpersonal psychotherapy (IPT) may be effective for PGD.A single 27‐year‐old Japanese woman lost her brother to suicide. However, she did not express her grief to anyone or visit a psychiatric clinic. After experiencing strong depressive symptoms triggered by work stress, she visited a psychiatric clinic, where she was diagnosed with depression as well as PGD. Through pharmacotherapy, her depressive symptoms improved, but no improvement was noted in her PGD symptoms. She therefore began IPT for PGD at our hospital, 5 years after her brother's suicide and after 4 years of PGD symptoms. In the introductory phase of IPT, she was diagnosed with comorbid persistent depressive disorder (PDD). After this diagnosis, through psychoeducation on PDD, she could identify the symptoms that reflected her personality traits as “PDD symptoms.” Furthermore, she could affirm her positive and negative feelings and share them with others. Consequently, the grieving process was facilitated, and her interests and relationships were re‐established. Her PGD and PDD symptoms improved.IPT may be effective for PGD comorbid with PDD among Japanese.","PeriodicalId":507124,"journal":{"name":"Psychiatry and Clinical Neurosciences Reports","volume":"8 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139196285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recurrent reactive hypoglycemia due to clozapine‐induced glucose intolerance: A case report 氯氮平诱发葡萄糖不耐受导致的复发性反应性低血糖：病例报告

Psychiatry and Clinical Neurosciences Reports Pub Date : 2023-12-01 DOI: 10.1002/pcn5.162

Fumihiko Kawai, Satsuki Watanabe, Hirotaka Ebihara, Naoki Shimizu, Shiori Oshima, Hiroshi Okai, Yoshiko Murata, Hisatoshi Arai, Koji Matsuo

引用次数: 0

Emerging trends in antipsychotic and antidepressant drug development: Targeting nonmonoamine receptors and innovative mechanisms 抗精神病和抗抑郁药物开发的新趋势：瞄准非单胺受体和创新机制

Psychiatry and Clinical Neurosciences Reports Pub Date : 2023-11-20 DOI: 10.1002/pcn5.157

Hitoshi Osaka, Tetsufumi Kanazawa

{"title":"Emerging trends in antipsychotic and antidepressant drug development: Targeting nonmonoamine receptors and innovative mechanisms","authors":"Hitoshi Osaka, Tetsufumi Kanazawa","doi":"10.1002/pcn5.157","DOIUrl":"https://doi.org/10.1002/pcn5.157","url":null,"abstract":"The domain of psychiatric drug development is currently witnessing a notable transformation, with a paramount emphasis on targeting nonmonoamine receptors and exploring inventive mechanisms of action. This paper presents an overview of the ongoing advancements in antipsychotic and antidepressant drug development. Historically, antipsychotics predominantly targeted dopamine receptors, but there is now an escalating interest in drugs that act on alternative receptors, exemplified by the TAAR1 receptor. One noteworthy candidate is Ulotaront (SEP‐363856), an agent acting as a TAAR1 agonist with 5‐HT1A agonist activity, demonstrating promising outcomes in the treatment of schizophrenia, devoid of extrapyramidal symptoms or metabolic side‐effects. Similarly, MIN‐101 (Roluperidone) and KarXT are currently in development, with its focus on addressing the symptoms in schizophrenia. In the domain of antidepressants, novel therapeutic approaches have surfaced, such as Auvelity, a Food and Drug Administration (FDA)‐approved NMDA receptor antagonist synergistically combined with Bupropion to enhance its effects. Another notable candidate is Zuranolone, operating as a GABA A receptor‐positive allosteric modulator, showcasing efficacy in treating major depressive disorder (MDD) and postpartum depression. Additionally, TAK‐653 (NBI‐1065845) and MJI821 (Onfasprodil) have emerged as potential antidepressants targeting AMPA receptors and NMDA receptor 2B (NR2B) negative allosteric modulation, respectively. This paper underscores the transformative potential of these novel drug candidates in psychiatric treatment and their ability to address cases that were previously treatment‐resistant. By focusing on nonmonoamine receptors and introducing innovative mechanisms, these drugs offer a promising prospect of improved outcomes for individuals suffering from schizophrenia and MDD. Thus, sustained attention and dedication to the development of such drugs are essential to augmenting the therapeutic options available for psychiatric patients.","PeriodicalId":507124,"journal":{"name":"Psychiatry and Clinical Neurosciences Reports","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139259329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of the Delusional Interpretation Scale and examination of related variables 妄想解释量表的编制及相关变量的研究

Psychiatry and Clinical Neurosciences Reports Pub Date : 2023-11-20 DOI: 10.1002/pcn5.156

Satsuki Ito, Junya Matsumoto, Ryota Hashimoto, Keiichiro Ishimaru

{"title":"Development of the Delusional Interpretation Scale and examination of related variables","authors":"Satsuki Ito, Junya Matsumoto, Ryota Hashimoto, Keiichiro Ishimaru","doi":"10.1002/pcn5.156","DOIUrl":"https://doi.org/10.1002/pcn5.156","url":null,"abstract":"Delusions are a common symptom in schizophrenia. Some scales have been developed to measure delusional tendencies in healthy people, and nonpathological delusional thinking can occur even among these individuals. The existing scales measure the presence and frequency of delusional thoughts, distress levels, and confidence levels. However, these scales are limited because they do not consider the context of the delusions (i.e., where, with whom, and when). In this study, we developed a new scale that presents detailed scenes using illustrations and sentences and measures the tendency toward delusional interpretations.Factor analysis was conducted to confirm the factor structure of the new scale. To examine the validity of the scale, we analyzed the correlations between delusional tendencies and related variables and verified the consistency between the current scale and previously developed tools.Factor analysis confirmed that the new scale has a two‐factor structure, including “internal attribution and paranoid tendency” and “external attribution tendency.” The new scale was found to have acceptable reliability and validity. The internal attribution and paranoid tendency factor was negatively correlated with self‐esteem and decentering. Furthermore, the internal attribution and paranoid tendency factor showed a moderate positive correlation with depressive state and anxiety tendency and a very weak positive correlation with experiences of bullying or harassment.The correlations between the new scale and related variables confirmed the construct validity and replicated the results reported in previous studies. This new scale enables the measurement of delusional tendencies in healthy subjects based on the social context.","PeriodicalId":507124,"journal":{"name":"Psychiatry and Clinical Neurosciences Reports","volume":"26 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139256265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delirium due to Trousseau syndrome treated with memantine and perospirone: A case report 使用美金刚和培哚匹隆治疗特鲁索综合征所致谵妄：病例报告

Psychiatry and Clinical Neurosciences Reports Pub Date : 2023-11-16 DOI: 10.1002/pcn5.159

Junji Yamaguchi, T. Hirayama, R. Sadahiro, Rika Nakahara, Hiromichi Matsuoka

引用次数: 0

Vortioxetine as a potential alternative for patients with escitalopram‐induced jitteriness/anxiety syndrome: A report of three cases 将伏替西汀作为艾司西酞普兰诱发的抖动/焦虑综合征患者的潜在替代药物：三个病例的报告

Psychiatry and Clinical Neurosciences Reports Pub Date : 2023-11-16 DOI: 10.1002/pcn5.158

K. Arai, Mari Nonaka, Shoko Shimada, Masayuki Nakamura

{"title":"Vortioxetine as a potential alternative for patients with escitalopram‐induced jitteriness/anxiety syndrome: A report of three cases","authors":"K. Arai, Mari Nonaka, Shoko Shimada, Masayuki Nakamura","doi":"10.1002/pcn5.158","DOIUrl":"https://doi.org/10.1002/pcn5.158","url":null,"abstract":"Jitteriness/anxiety syndrome is a recognized adverse effect observed during the initiation or change of dose in antidepressant treatment. Managing patients who develop this syndrome remains a challenge. While escitalopram is a widely used antidepressant known to cause these symptoms, this report explores vortioxetine as a therapeutic alternative.Three distinct clinical scenarios were observed in patients who manifested jitteriness/anxiety syndrome while on escitalopram treatment for depression. Patient A was initiated on escitalopram and experienced an initial alleviation in depressive symptoms, but 3 months later displayed mood elevation, talkativeness, and increased activity, which disturbed his daily life. A transition to vortioxetine subsequently resolved the mood elevation. Patient B exhibited elevated mood, hyperactivity, irritability, and talkativeness just 6 days post‐initiation of treatment with escitalopram. After the discontinuation of escitalopram and unsuccessful trials with aripiprazole, lurasidone, and lamotrigine, her depressive mood intensified, culminating in suicidal ideation. Starting vortioxetine led to a consistent improvement of her symptoms, and she resumed work and was emotionally stable. Patient C was initially diagnosed with bipolar disorder and faced a relapse into depression despite undergoing various treatments. After 2 weeks on escitalopram, she exhibited irritability and self‐harm urges. Three months later, after being re‐diagnosed with depressive disorders with anxious distress, vortioxetine was administered, which significantly reduced her depressive symptoms and allowed her to continue her education.Vortioxetine presents as a promising therapeutic alternative that is worth considering for patients with escitalopram‐induced jitteriness/anxiety syndrome.","PeriodicalId":507124,"journal":{"name":"Psychiatry and Clinical Neurosciences Reports","volume":"1 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139269627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0